From the Critical Medicines Act to the Biotech Act, Brussels is looking to strengthen Europe’s resilience, innovation capacity and global competitiveness in the life sciences sector. At the same time, the EU is placing greater emphasis on prevention and cardiovascular health as part of a broader shift towards long-term health sustainability.

In this first episode of EU Advantage Healthcare, Grayling Brussels launches a new monthly series dedicated to the key healthcare debates shaping the EU agenda. Each month, our experts will unpack the latest policy developments, political dynamics and regulatory priorities emerging from Brussels.

EU Advantage Healthcare is Grayling Brussels’ podcast exploring the policy choices, legislative developments and political priorities shaping Europe’s healthcare environment. Listen on Spotify and follow @Grayling on LinkedIn for the latest updates, insights and conversations.